Climb Bio Inc Dossier - Source-backed chat

Climb Bio Inc

CLYMNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.39

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $11.07Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $635.8M

Enterprise Value $591.7M

Shares Outstanding 57.4M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Climb Bio, Inc. (NASDAQ: CLYM) is a high-potential, clinical-stage biotechnology company developing targeted monoclonal antibodies for immune-mediated diseases. The investment thesis is anchored on its lead asset, budoprutug (an anti-CD19 mAb), which has demonstrated robust clinical proof-of-concept in immune thrombocytopenia (ITP) with exceptional B-cell depletion and durable platelet responses. Backed by a strong cash runway extending into 2028 following a $110 million private placement in April 2026, Climb Bio is well-positioned to navigate multiple high-impact clinical readouts in late 2026 across pMN, SLE, and ITP without near-term dilution risk.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets14 analysts · as of 18 Aug 2026

Low · most bearish analyst$15.00

Mean target$20.93

High · most bullish analyst$35.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$9.0020%

Upcoming clinical readouts for budoprutug in pMN or SLE show safety concerns (e.g., severe infusion-related reactions or infections) or fail to show differentiated efficacy compared to existing therapies like rituximab. Clinical timelines slip, and cash burn accelerates, shortening the runway and forcing dilutive financing before pivotal trials.

Base CaseCentral scenario

$20.1550%

Budoprutug continues to show solid, competitive efficacy and clean safety profiles in ongoing trials, confirming its therapeutic potential in B-cell mediated diseases. The company achieves its planned 2026 milestones, and the stock moves toward the consensus analyst target as clinical de-risking progresses.

Bull CaseUpside scenario

$35.0030%

Budoprutug delivers outstanding Phase 2 data in primary membranous nephropathy (pMN) and Phase 1b data in SLE in Q4 2026, demonstrating best-in-class B-cell depletion and clinical remission. CLYM116 successfully transitions to Phase 2 for IgA nephropathy with strong PK/PD support. The company becomes a highly attractive acquisition target for large pharmaceutical companies expanding their autoimmune pipelines, driving significant valuation upside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong clinical proof-of-concept for lead asset budoprutug, showing >90% B-cell depletion and durable platelet responses in heavily pretreated ITP patients.
Robust balance sheet with cash runway extending into 2028, bolstered by a $110 million private placement in April 2026.
Multiple near-term clinical catalysts in H2 2026 across three distinct indications (pMN, ITP, SLE) and two assets (budoprutug, CLYM116).
Favorable regulatory designations, including FDA Fast Track and Orphan Drug designations for budoprutug in pMN.

Key Investment Risks

High clinical development risk inherent to pre-commercial biotechnology companies; failure in any of the ongoing Phase 1b or Phase 2 trials would severely impact valuation.
Intense competition in the autoimmune and B-cell depletion space from established therapies and other next-generation pipeline candidates.
Dependence on external capital markets for long-term funding once the current cash runway is exhausted.

Thesis Invalidation Triggers

Failure of budoprutug to achieve meaningful B-cell depletion or clinical efficacy in the upcoming pMN Phase 2 or SLE Phase 1b readouts in Q4 2026.
Emergence of serious, unexpected adverse events in clinical trials leading to FDA clinical holds.
Significant delays in patient enrollment or clinical trial execution that push key data readouts past 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.